Long term results of Alliance A041202 show continued advantage of ibrutinib-based regimens compared with bendamustine plus rituximab chemoimmunotherapy
      Google Scholar   
Citation:
Blood vol 138 (Supplement 1) 639
Meeting Instance:
ASH 2021
Year:
2021
Type:
Abstract
Sub type:
Oral
Funding:
NCTN
Endpoint:
Primary
Analysis:
Long-Term-Followup
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epub
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Parents:
None
Children:
3856   4061  
Program:
OGC
Primary Committee:
Leukemia
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, U24CA196171, K23CA178183, R01CA183444, U10CA180863 (CCTG), U10CA180820 (ECOG-ACRIN), U10CA180888 (SWOG);  
Corr. Author:
 
Authors:
                                                       
Networks:
IL017, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-NC010, LAPS-OH007, NC002, NY167, OH070   
Study
Alliance-A041202
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: